Cite
HARVARD Citation
Teply, B. et al. (2018). Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet oncology. 19 (1), pp. 76-86. [Online].